SGLT-2 Inhibitors and Lower Urinary Tract Symptoms | NCT07716774

NCT07716774

Overview

NCT ID: NCT07716774
Lead Sponsor: Marmara UniversityOTHER
Official Title: Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Lower Urinary Tract Symptoms
Brief Summary: This prospective observational study aims to evaluate the effects of sodium-glucose cotransporter 2 (SGLT-2) inhibitors on lower urinary tract symptoms (LUTS) in patients with type 2 diabetes mellitus. Patients who are newly initiated on SGLT-2 inhibitor therapy as part of routine clinical care will be evaluated at baseline and after one month using a 3-day bladder diary and the Overactive Bladder Questionnaire (OAB-v8). Changes in storage symptoms, including urinary frequency, urgency, nocturia, and urinary incontinence, will be assessed to better characterize the impact of SGLT-2 inhibitor therapy on LUTS.
Conditions: SGLT2 Inhibitors
Lower Urinary Track Symptoms
Overactive Bladder

Ages Eligible for Study: Adult (18-64)Older Adult (65+)
Sexes Eligible for Study: All
Accepts Healthy Volunteers?: Yes
Eligibility Criteria: Inclusion Criteria:

Adults (≥18 years of age)

Patients with type 2 diabetes mellitus newly initiated on oral SGLT-2 inhibitor therapy

Exclusion Criteria:

Age <18 years

Patients with insulin-dependent diabetes mellitus (IDDM)

Patients with diabetes-related complications (e.g., diabetic nephropathy, retinopathy, or vasculopathy)

Patients receiving anticholinergic or α-blocker therapy for lower urinary tract symptoms (LUTS)

History of urinary incontinence surgery (including any surgical procedure involving the urethral sphincter, bladder neck, pelvic floor, or pelvic nerves)

Patients with urinary tract infection (UTI)